Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 5
2004 7
2005 6
2006 6
2007 11
2008 2
2009 8
2010 7
2011 8
2012 10
2013 22
2014 23
2015 20
2016 22
2017 26
2018 29
2019 43
2020 75
2021 86
2022 82
2023 98
2024 41

Text availability

Article attribute

Article type

Publication date

Search Results

580 results

Results by year

Filters applied: . Clear all
Page 1
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer.
Morganti S, Jin Q, Vincuilla J, Buehler R, Ryan S, Stokes S, Parker T, Mittendorf EA, King TA, Weiss A, Partridge AH, Bychkovsky BL, Curigliano G, Tayob N, Lin NU, Garber JE, Tolaney SM, Lynce F. Morganti S, et al. Among authors: curigliano g. NPJ Breast Cancer. 2024 Apr 16;10(1):28. doi: 10.1038/s41523-024-00632-8. NPJ Breast Cancer. 2024. PMID: 38627457 Free PMC article.
Venous thromboembolism in pancreatic neuroendocrine neoplasm: a cohort study.
Gervaso L, Laffi A, Gaeta A, Gandini S, Boldrini L, Meneses-Medina MI, Rubino M, Benini L, Borghesani M, Algeri L, Curigliano G, Spada F, Cella CA, Fazio N. Gervaso L, et al. Among authors: curigliano g. Res Pract Thromb Haemost. 2024 Mar 15;8(3):102381. doi: 10.1016/j.rpth.2024.102381. eCollection 2024 Mar. Res Pract Thromb Haemost. 2024. PMID: 38617046 Free PMC article. No abstract available.
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.
Leon-Ferre RA, Jonas SF, Salgado R, Loi S, de Jong V, Carter JM, Nielsen TO, Leung S, Riaz N, Chia S, Jules-Clément G, Curigliano G, Criscitiello C, Cockenpot V, Lambertini M, Suman VJ, Linderholm B, Martens JWM, van Deurzen CHM, Timmermans AM, Shimoi T, Yazaki S, Yoshida M, Kim SB, Lee HJ, Dieci MV, Bataillon G, Vincent-Salomon A, André F, Kok M, Linn SC, Goetz MP, Michiels S; International Immuno-Oncology Biomarker Working Group. Leon-Ferre RA, et al. Among authors: curigliano g. JAMA. 2024 Apr 2;331(13):1135-1144. doi: 10.1001/jama.2024.3056. JAMA. 2024. PMID: 38563834
Comparison of long-term outcome between clinically high risk lobular versus ductal breast cancer: a propensity score matched study.
Magnoni F, Corso G, Maisonneuve P, Bianchi B, Accardo G, Sangalli C, Massari G, Rotili A, Nicosia L, Pesapane F, Montagna E, Mazzarol G, Galimberti V, Veronesi P, Curigliano G. Magnoni F, et al. Among authors: curigliano g. EClinicalMedicine. 2024 Mar 20;71:102552. doi: 10.1016/j.eclinm.2024.102552. eCollection 2024 May. EClinicalMedicine. 2024. PMID: 38545425 Free PMC article.
PARP Inhibitors for Breast Cancer Treatment: A Review.
Morganti S, Marra A, De Angelis C, Toss A, Licata L, Giugliano F, Taurelli Salimbeni B, Berton Giachetti PPM, Esposito A, Giordano A, Bianchini G, Garber JE, Curigliano G, Lynce F, Criscitiello C. Morganti S, et al. Among authors: curigliano g. JAMA Oncol. 2024 Mar 21. doi: 10.1001/jamaoncol.2023.7322. Online ahead of print. JAMA Oncol. 2024. PMID: 38512229
Corrigendum to "Breaking barriers in triple negative breast cancer (TNBC) - Unleashing the power of antibody-drug conjugates (ADCs)" [Cancer Treatment Reviews 123 (2024) 102672].
Dri A, Arpino G, Bianchini G, Curigliano G, Danesi R, De Laurentiis M, Del Mastro L, Fabi A, Generali D, Gennari A, Guarneri V, Santini D, Simoncini E, Zamagni C, Puglisi F. Dri A, et al. Among authors: curigliano g. Cancer Treat Rev. 2024 Apr;125:102714. doi: 10.1016/j.ctrv.2024.102714. Epub 2024 Mar 16. Cancer Treat Rev. 2024. PMID: 38493647 No abstract available.
580 results